Consumer spending has long been the engine of the US economy, which is what made the social lockdown policies put in place against COVID so devastating. By forcing the public to stay home, politics is effectively shutting down the main source of economic activity. Fortunately, we are now on the upswing. COVID is on the decline, most restrictions have been or are being lifted, and economic activity is starting to boom again. A deluge of cash from stimulus checks, tax credits and accumulated savings has put consumers in a buying mood. Wells Fargo Chief Economist Jay Bryson notes that the combination of cash and the end of winter “resulted in a blockbuster month for retailers in March. Total retail sales rose 9.8% for the month, a gain only matched by the surge tied to the reopening of the economy in May last year after the lockdowns. The profit increased total sales an impressive 17% higher than before the pandemic. “Bryson sees cause for caution as he indicates that the stimulus money has been sent and most of the money has been spent. He now describes the effect as “fading”. However, he adds that the accumulated consumer savings have the potential to outweigh the decline in government economic reviews. “Excess savings coupled with the expected reopening of the service economy this summer supports our forecast for a consumption boom this year that will not match any living memory,” said Bryson. Wells Fargo stock analysts have also been busy trying to find the stocks that will rise in the environment Bryson describes. We used the TipRanks platform to look up two of these Wells Fargo picks. These are stocks with a buy rating and high upside potential. We’re talking about a return of at least 60% over the next 12 months. Bloom Energy (BE) We’ll start with a look at Bloom Energy, a “green” alternative energy company. Bloom produces solid oxide fuel cells, an alternative technology to current batteries or petro-fuels. Solid oxides generate electrical energy through electrochemical conversion, which has the advantages of energy efficiency and low emissions. Their main disadvantage is a high operating temperature. To date, Bloom has installed fuel cells with a capacity of around 600 megawatts. Bloom’s business began to accelerate towards the end of 2020, according to the company’s financial results. The fourth quarter returned quarterly return on sales of $ 249.4 million, the best in over two years and an increase of 16.8% year over year. The successful fourth quarter was due to a 16.6% increase in order intake. Earlier this year, Bloom joined ten other legacy energy companies in an initiative called Hydrogen Forward to promote the development of hydrogen fuel sources and lobbying for industry in Washington. The formation of the coalition signals that hydrogen energy companies are determined to make their voices heard – and with the commitment of the new Biden government to a “green” economy, Bloom and his partners could find sympathetic ears in the capital. Meanwhile, Wells Fargo analyst Praneeth Satish is launching coverage of the stock with an overweight (i.e. buy) with a target price of $ 43, implying an uptrend of 69% for a year. (To view Satish’s track record, click here.) “The company has a successful track record of cutting costs as it has reduced its Cost / kW by ~ 60% over the past 5 years. We believe that gross margin will continue to improve and expect BE to be generated. ” Positive cash flow from operating activities in 2021. Additionally, we believe BE ~ 1 year away from making FCF positive. Note that cost reductions and economies of scale should also benefit BE’s expansion initiatives as solid oxide technology is used in all of the new areas identified – applications with limited incremental R&D or manufacturing investment, “wrote Satish. Wells Fargo believes we turn now the rest of the road to: BE’s 5 buys and 3 holds merge into a moderate buy rating, and assuming the average target price of $ 34.80, the shares are expected to decline at a premium of 37% over the next 12 months Change hands. (See BE inventory analysis on TipRanks.) Affimed (AFMD) We’re shifting gears for the next inventory. Affimed is an immuno-oncology researcher in the biopharma world searching for new therapies for cancer patients. The ROCK (Redirected Optimized The company’s Cell Killing) is used to develop innate cell engagers capable of their own Reactivate the patient’s immune cells to fight tumors. The company has 6 separate programs in its development pipeline, most of them in the preclinical research phase. The company’s focus is on the treatment of hematological and solid tumors. Of Affimed’s drug candidates, AFM13 is the first to reach clinical trial stage. The candidate currently has trials for the treatment of peripheral T-cell lymphoma and CD30-positive T-cell lymphoma, as well as transformed mycosis fungoids. Other lines of research are in earlier stages of development. AMF13 is a CD16A-based innate cell engager and promises a certain therapeutic effectiveness as well as a favorable safety profile. In March, Affimed announced that REDIRECT, a phase 2 study of AFM13 for the treatment of CD30-positive T-cell lymphoma, is continuing. So far, the study has shown some anti-tumor response in both Cohort A and Cohort B of the patient base. Affimed’s most recent program update also showed significant progress in AFM24, the company’s second largest program currently in a Phase 1 study of effectiveness against solid tumors. In his report on Affimed for Well Fargo, analyst Nick Abbott rates the stock as overweight (i.e. buy) with a target price of $ 18, which indicates potential for a 62% uptrend in the coming year. Abbott confirms its stance: “Our assessment of AFMD with obesity reflects our view of AFMD’s approach to immuno-oncology (IO), with an emphasis on the ROCK innate cell development platform that supports the development of bispecific antibodies as monotherapy Combination with checkpoint inhibitors and in combination with cell therapy. In our opinion, a positive interim analysis of the registration-driven REDIRECT study by AFM13 provides a validation of the ROCK platform. “Wall Street analysts are unanimous on this and have given the stock 5 positive ratings in the past few weeks for a strong buy consensus rating. The stocks are priced at $ 10.42 and their average target of $ 14 implies an uptrend of ~ 25% for a year. (See AFMD stock analysis on TipRanks.) To find great ideas for trading stocks at attractive valuations, visit TipRanks ‘Best Stocks to Buy, a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.